Loading insider details...
Beta
Latest Form 4 (Sep 2, 2026): Grant/Award of 8,320 ERNA shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 2, 2026 | Ernexa Therapeutics Inc. (ERNA) | Grant/Award | 8,320 | n/a |
| Jun 29, 2026 | Erasca, Inc. (ERAS) | Grant/Award | 29,888 | n/a |
| Jan 5, 2026 | Erasca, Inc. (ERAS) | Grant/Award | 37,762 | n/a |
| Jun 26, 2025 | Erasca, Inc. (ERAS) | Grant/Award | 120,000 | n/a |
| Feb 10, 2025 | Eterna Therapeutics Inc. (ERNA) | Grant/Award | 72,074 | n/a |
| Jan 3, 2025 | Erasca, Inc. (ERAS) | Grant/Award | 45,678 | n/a |
| Jun 21, 2024 | Erasca, Inc. (ERAS) | Grant/Award | 60,000 | n/a |
| Jun 11, 2024 | Deciphera Pharmaceuticals, Inc. | Disposition to Issuer | 22,150 | n/a |
| Apr 29, 2024 | Eterna Therapeutics Inc. (ERNA) | Grant/Award | 124,525 | n/a |
| Jan 3, 2024 | Erasca, Inc. (ERAS) | Grant/Award | 62,747 | n/a |